Thyroid associated ophthalmopathy - A review

Malaysian Family Physician

Volumn 4, Issue 1, 2009, Pages

  Mallika, P S ^a   Tan, A K ^a   Aziz, S ^b   Syed Alwi, S A R ^a   Chong, M S ^b   Vanitha, R ^b   Intan, G ^b  

^a UNIVERSITI MALAYSIA SARAWAK   (Malaysia)

^b SARAWAK GENERAL HOSPITAL   (Malaysia)

Author keywords

Autoimmunity; Corticosteroids; Radiotherapy; Rehabilitative surgery; Smoking; Surgical decompression; Thyroid eye disease

Indexed keywords

EID: 68949172541     PISSN: 1985207X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Gleeson H, Kelly W, Toft A, et al. Severe thyroid eye disease associated with primary hypothyroidism and thyroid-associated dermopathy. Thyroid. 1999; 9(11):1115-8 [PubMed]
2. Salvi M, Zhang Z-G, Haegert D, et al. Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunologic abnormalities. J Clin Endocrinol Metab. 1990; 70(1):89-94 [PubMed]
3. Kemp EH, Ridgway JN, Smith KA, et al. Autoantibodies to the flavoprotein subunit of succinate dehydrogenase: Analysis of specificity in autoimmune thyroid disease. Clin Endocrinol (Oxf). 2000;53(3):291-9 [PubMed] [Full text]
4. Burch HB, Wartofsky L. Graves' ophthalmopathy: Current concepts regarding pathogenesis and management. Endocr Rev. 1993;14(6):747-93 [PubMed]
5. Larsen PR, Davies TF, Hay ID. The thyroid gland. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, editors. Williams textbook of Endocrinology. Philadelphia: WB Saunders Company; 1998. page 389-515
6. Bahn RS, Heufelder AE. Mechanisms of disease: Pathogenesis of Graves' ophthalmopathy. N Eng J Med. 1993;329(20):1468-75 [PubMed]
7. Bartley GB. The epidemiological characteristics and clinical course of ophthalmology associated with autoimmune thyroid disease in Olmsted Country, Minnesota. Trans Am Ophthalmol Soc. 1994;92:477-588 [PubMed] [Full text]
8. Lim SL, Lim AK, Mumtaz M, Hussein E, Wan Bebakar WM, Khir AS. Prevalence, risk factors, and clinical features of thyroid-associated ophthalmopathy in multiethnic Malaysian patients with Graves' disease. Thyroid. 2008;18(12):1297-301 [PubMed]
9. Forbes G, Gorman CA, Brennan MD, et al. Ophthalmopathy of Graves' disease: Computerized volume measurements of the orbital fat and muscle. AJNR Am Neuroradiol. 1986;7(4):651-6 [PubMed]
10. Perros P, Crombie AL, Matthews JNS, et al. Age and gender influence the severity of the the thyroid-associated ophthalmopathy: A study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf). 1993;38(4):367-72 [PubMed]
11. Krassas GE, Segni M, Wiersinga WM. Childhood Graves' ophthalmopathy: Results of a European questionnaire study. Eur J Endocrinol. 2005;153(4):515-21 [PubMed] [Full text]
12. Kendall-Taylor P, Perros P. Clinical presentation of thyroid associated orbitopathy. Thyroid 1998; 8(5):427-8 [PubMed]
13. Marcocci C, Bartalena L, Bogazzi F, et al. Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinol (Copenh). 1989;120(4):473-8 [PubMed]
14. th ed. New York: Har-Row; 1978. page 663-70
15. Inoue D, Sato K, Maeda M, et al. Genetic differences shown by HLA typing among Japanese patients with euthyroid Graves' ophthalmopathy, Graves' disease and Hashimoto's thyroiditis: Genetic characteristics of euthyroid Graves' ophthalmopathy. Clin Endocrinol (Oxf). 1991;34(1):57-62 [PubMed]
16. Weetman AP, Zhang L, Webb S, et al. Analysis of HLA-DQB and HLA-DPB alleles in Graves' disease by oligonucleotide probing of enzymatically amplified DNA. Clin Endocrinol (Oxf). 1990;33(1):65-71 [PubMed]
17. Payami H, Joe S, Farid NR, et al. Relative predispositional effects (RPEs) of marker allele with disease: HLA-DR alleles and Graves' disease. Am J Hum Genet. 1989;45(4):541-6 [PubMed] [Full text]
18. Weetman AP, So AK, Warner CA, et al. Immunogenetics of Graves' ophthalmopathy. Clin Endocrinol (Oxf). 1988;28(6):619-28 [PubMed]
19. Hagg E, Asplund K. Is endocrine ophthalmopathy related to smoking? Br Med J. 1987;295:634-5 [PubMed] [Full text]
20. Prummel MF, Wiersinga WM. Smoking and risk of Graves'disease. JAMA. 1993; 269(4):479-82 [PubMed]
21. Bartalena L, Bogazzi F, Tanda ML, et al. Cigarette smoking and thyroid. Eur J Endocrinol. 1995; 133(5):507-12 [PubMed]
22. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: Impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf). 1996; 45(4):477-81 [PubMed]
23. Bartalena L, Martina E, Marcocci C, et al. More on smoking habits and Graves' ophthalmopathy. J Endocrinol Invest. 1989; 12(10):733-7 [PubMed]
24. Metcalfe RA, Weetman AP. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: Possible role in thyroid associated ophthalmopathy. Clin Endocrinol (Oxf). 1994;40(1):67-72 [PubMed]
25. Cawood TJ, Moriarty P, O'Farrelly C, et al. Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link. J Clin Endocrinol Metab. 2007;92(1):59-64 [PubMed] [Full text]
26. Thornton J, Kelly SP, Harrison RA, et al. Cigarette smoking and thyroid eye disease: a systematic review. Eye. 2007;21(9):1135-45 [PubMed]
27. Hegedius L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves' ophthalmopathy. J Endocrinol Invest. 2004;27(3):265-71 [PubMed]
28. McKenzie JM. Pathogenesis of Graves' disease: Role of the long -acting thyroid stimulator. J Clin Endocrinol Metab. 1965; 25:424-61 [PubMed]
29. Hoffman MJ, Hetzel BS. The clinical significance of plasma thyroid-stimulating activity in hyperthyroidism. Australas Ann Med. 1966;15(3):204-9 [PubMed]
30. Heufelder AE, Joba W. Thyroid-associated eye disease. Strabismus. 2000;8(2):101-11 [PubMed]
31. Van Dyk HJ. Orbital Graves' disease: A modification of the "NO SPECS" classification. Ophthalmology. 1981;88(6):479-83 [PubMed]
32. Sharanjeet-Kaur, Dickinson CM, O'Donoghue E, et al. Spectral sensitivity in patients with dysthyroid eye disease. Ophthalmic Physiol Opt. 1997;17(3):232-8 [PubMed]
33. Bartley GB. Evolution and classification systems for Graves' ophthalmopathy. Ophthal Plast Reconstr Surg. 1995;11(4):229-37 [PubMed]
34. Bartley GB. The differential diagnosis and classification of eyelid retraction. Ophthalmology. 1996;103(1):168-76 [PubMed]
35. Danesh-Meyer HV, Savino PJ, Deramo V, et al. Intraocular pressure changes after treatment for Graves' orbitopathy. Ophthalmology. 2001;108(1):145-50 [PubMed]
36. Jordan DR, Anderson RL. Orbital decompression. Ophthalmic Plast Reconstr Surg. 2000;16(2):167-8 [PubMed]
37. Fatourechi V. Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol. 2005;6(5):295-309 [PubMed]
38. Garrity JA, Fatourechti V, Bergstralh EJ, et al. Results of transantral orbital decompression in 428 patients with severe Graves'ophthalmopathy. Am J Ophthalmol. 1993;116(5):533-47 [PubMed]
39. Gilbard JP, Farris RL. Ocular surface drying and tear film osmolarity in thyroid eye disease. Acta Ophthalmol (Copenh). 1983;61(1):108-16 [PubMed]
40. Trobe JD, Glaser JS, Laflamme P. Dysthyroid optic neuropathy. Clinical profile and rationale for management. Arch Ophthalmol. 1978;96(7):1199-209 [PubMed]
41. Trobe JD. Optic nerve involvement in dysthyroidism. Ophthalmology. 1981;88(6):488-92 [PubMed]
42. Warren JD, Spector JG, Burde R. Long-term follow up and recent observations on 305 cases of orbital decompression for dysthyroid orbitopathy. Laryngoscope. 1989;99(1):35-40 [PubMed]
43. Behrouzi Z, Rabei HM, Azizi F, et al. Prevalence of open-angle glaucoma, glaucoma suspect, and ocular hypertension in thyroid-related immune orbitopathy. J Glaucoma. 2007;16(4):358-62 [PubMed]
44. Werner SC. Modification of the classification of the eye changes of Graves' disease. Am J Ophthalmol. 1977;83(5):725-7 [PubMed]
45. Wiersinga WM, Prummel MF, Mourits MP, et al. Classification of the eye changes of Graves' disease. Thyroid. 1991;1(4):357-60 [PubMed]
46. Wall JR, Henderson J, Strakosch CR, et al. Graves' ophthalmopathy. Can Med Assoc J. 1981;124(7):855-62, 866 [PubMed] [Full text]
47. Teng CS, Smith BR, Clayton B, et al. Thyroid-stimulating immunoglobulins in ophthalmic Graves' disease. Clin Endocrinol (Oxf). 1977;6(3):207-11 [PubMed]
48. Wall JR, Odgers RJ, Hetzel BS. Immunological studies of the eye changes of thyrotoxicosis. Aust NZ J Med. 1973;3(2):162-8 [PubMed]
49. Bahn RS, Garrity JA, Gorman CA. Diagnosis and management of Graves' ophthalmopathy. J Clin Endocrinol Metab. 1990;71(3):559-63 [PubMed]
50. Bahn RS, Gorman CA. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am. 1987;16(2):391-407 [PubMed]
51. Bartalena L, Marcocci, Bogazzi F, et al. Glucocorticoid therapy of Graves' ophthalmopathy. Exp Clin Endocrinol. 1991;97(2-3):320-7 [PubMed]
52. Wiersinga WM. Graves' ophthalmopathy. Thyroid Int. 1997;3:1-15
53. Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: Results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab. 2001;86(8):3562-7 [PubMed] [Full text]
54. Hiromatsu Y. Steroid therapy for Graves' ophthalmopathy. Nippon Rinsho. 2006;64(12):2279-85 [PubMed]
55. Bartalena L, Marcocci C, Manetti L, et al. Orbital radiotherapy for Graves' ophthalmopathy. Thyroid. 1998;8(5):439-41 [PubMed]
56. Pinchera A, Bartalena L, Chiovato L, et al. Radiotherapy of Graves' ophthalmopathy. In: Gorman CA, Waller RR, Dyer JA, editors. The eye and the orbit in thyroid disease. New York: Raven Press; 1984:301-16
57. Kahaly G, Roesler HP, Pitz S, et al. Low-versus high dose radiotherapy for Graves' ophthalmopathy: A randomized single blind trial. J Clin Endocrinol Metab. 2000;85(1):102-8 [PubMed] [Full text]
58. Wei RL, Cheng JW, Cai JP. The use of orbital radiotherapy for Graves' ophthalmopathy: Quantitative review of the evidence. Ophthalmologica. 2008;222(1):27-31 [PubMed]
59. Kulwin DR, Cotton RT, Kersten RC. Combined approach to orbital decompression. Otolaryngol Clin North Am. 1990;23(3):381-90 [PubMed]
60. Krassas GE, Doumas A, Kaltsas T, et al. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease. Thyroid. 1999;9(1):47-52 [PubMed]
61. Prummel MF, Mouritis MP, Berghout A, et al. Prednisolone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med. 1989; 321(20):1353-9 [PubMed]
62. Leibe A, Levy Y, Shoenfeld Y. Intravenous immunoglobulins treatment of patients with Graves' ophthalmopathy. Harefuah. 2001;140(5):392-4,455,454 [PubMed]
63. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid. 2002;12(10):855-60 [PubMed]